Resource Center

This section contains international research and may reference indications not approved in all regions. Please consult local approved indications before use.

Filter By:

Search
resources-top-bg
The Pulsenmore platform demonstrates strong clinical evidence for safety, efficacy, and usability in home-based fetal well-being monitoring.
This randomized controlled study evaluates the efficacy of prelabor visual biofeedback using a self-operated home ultrasound device to enhance maternal pushing and improve obstetrical outcomes.
BPP, obtained by the Pulsenmore ES ultrasound device, operated by lay users, during synchronized telehealth guidance, demonstrates high accuracy and reliability for clinical use compared to standard BPP.

Request the document

Click On The Read More Below To Request The Document

Click On The Read More Below To Request The Document

resources-bottom-bg

the news pulse

We invite you to keep up to date with the latest updates by registering to our quarterly newsletter

news-pulse-doctor
news-pulse-lady1
news-pulse-couple
news-pulse-lady2
about-collaborations-bottom-bg

FAQ

Frequently asked question

The Pulsenmore was designed to follow ALARA (As Low As Reasonably Achievable) principles as follows:

The system supports only low frequency (2-5MHz), the duration of the scan is limited up to 3 minutes in the App guided mode, or at the clinician’s discretion in the clinician guided mode, only clinician can modify the ultrasound parameters (i.e., depth, gain, frequency etc.), each scan is enabled only upon the approval of a medical professional. The system was authorized by FDA through the de novo classification process.